Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells

American Journal of Gastroenterology

Volumn 103, Issue 4, 2008, Pages 825-837

  Ogunwobi, Olorunseun O ^b   Beales, Ian L P ^a,b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CASPASE 3; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHOTRANSFERASE; PRAVASTATIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; RAS PROTEIN; SIMVASTATIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CARCINOMA CELL; CELL COUNT; CELL LINE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; NUCLEOSOME; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BARRETT ESOPHAGUS; CASPASE 3; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOBLOTTING; LOVASTATIN; MEVALONIC ACID; NITROBENZENES; POLYISOPRENYL PHOSPHATES; PRAVASTATIN; PROTEIN KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SESQUITERPENES; SIGNAL TRANSDUCTION; SIMVASTATIN; SULFONAMIDES;

EID: 41849115563     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01773.x     Document Type: Article

References (51)

1. Buttar NS, Wang KK. Mechanisms of disease: Carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 2004 1 : 106 2.
2. Jankowski JA, Perry I, Harrison RF. Gastro-oesophageal cancer: Death at the junction. BMJ 2000 321 : 463 4.
3. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review. JAMA 2002 287 : 1972 81.
4. Powell J, McConkey CC, Gillison EW, et al. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 2002 102 : 422 7.
5. Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association technical review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005 128 : 1471 505.
6. Allum WH, Griffin SM, Watson A, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2002 50 (Suppl 5 V1 23.
7. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999 130 : 883 90.
8. Calle EE, Thun MJ. Obesity and cancer. Oncogene 2004 23 : 6365 78.
9. Agarwal B, Bhendwal S, Halmos B, et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999 5 : 2223 9.
10. Wu J, Wong WW, Khosravi F, et al. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004 64 : 6461 8.
11. Graaf MR, Richel DJ, van Noorden CJ, et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004 30 : 609 41.
12. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996 275 : 55 60.
13. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004 364 : 771 7.
14. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005 352 : 2184 92.
15. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 2000 160 : 2363 8.
16. Khurana V, Sheth A, Caldito G, et al. Statins reduce the risk of pancreatic cancer in humans: A case-control study of half a million veterans. Pancreas 2007 34 : 260 5.
17. Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res 2001 61 : 4885 91.
18. van de Donk NW, Kamphuis MM, Lokhorst HM, et al. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002 16 : 1362 71.
19. Zhong WB, Wang CY, Chang TC, et al. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003 144 : 3852 9.
20. Ghosh PM, Ghosh-Choudhury N, Moyer ML, et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 1999 18 : 4120 30.
21. Bouterfa HL, Sattelmeyer V, Czub S, et al. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 2000 20 : 2761 71.
22. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000 6 : 2044 52.
23. Tselepis C, Morris CD, Wakelin D, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: Induction of c-myc by acidified bile acid in vitro. Gut 2003 52 : 174 80.
24. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006 147 : 4505 16.
25. Abdalla SI, Sanderson IR, Fitzgerald RC. Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis 2005 26 : 1627 33.
26. Souza RF, Shewmake K, Terada LS, et al. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002 122 : 299 307.
27. Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000 60 : 5767 72.
28. Beales IL. Gastrin and interleukin-1beta stimulate growth factor secretion from cultured rabbit gastric parietal cells. Life Sci 2004 75 : 2983 95.
29. Tang D, Park HJ, Georgescu SP, et al. Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sci 2006 79 : 1484 92.
30. Ogunwobi OO, Beales IL. Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways. Regul Pept 2006 134 : 1 8.
31. Casciola-Rosen L, Nicholson DW, Chong T, et al. Apopain/CPP32 cleaves proteins that are essential for cellular repair: A fundamental principle of apoptotic death. J Exp Med 1996 183 : 1957 64.
32. Beales IL, Ogunwobi O. Glycine-extended gastrin inhibits apoptosis in colon cancer cells via separate activation of Akt and JNK pathways. Mol Cell Endocrinol 2006 247 : 140 9.
33. Ogunwobi OO, Beales ILP. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006 134 : 105 13.
34. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990 343 : 425 30.
35. Stepan V, Ramamoorthy S, Pausawasdi N, et al. Role of small GTP binding proteins in the growth-promoting and antiapoptotic actions of gastrin. Am J Physiol Gastrointest Liver Physiol 2004 287 : G715 25.
36. Beales ILP, Ogunwobi O, Camceron E, et al. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: A functional and immunohistochemical study. BMC Cancer 2007 7 : 97.
37. Souza RF, Shewmake K, Pearson S, et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2004 287 : G743 8.
38. Jaiswal K, Lopez-Guzman C, Souza RF, et al. Bile salt exposure increases proliferation through p38 and ERK-MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006 290 : G335 42.
39. Nishida S, Matsuoka H, Tsubaki M, et al. Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Mol Cell Biochem 2005 269 : 109 14.
40. Cerezo-Guisado MI, Garcia-Marin LJ, Lorenzo MJ, et al. Lovastatin inhibits the growth and survival pathway of phosphoinositide 3-kinase/protein kinase B in immortalized rat brain neuroblasts. J Neurochem 2005 94 : 1277 87.
41. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002 122 : 1101 12.
42. Wong WW, Tan MM, Xia Z, et al. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001 7 : 2067 75.
43. Wachtershauser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001 22 : 1061 7.
44. Pan HY, DeVault AR, Wang-Iverson D, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990 30 : 1128 35.
45. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003 9 : 10 9.
46. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001 57 : 357 64.
47. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996 2 : 483 91.
48. Larner J, Jane J, Laws E, et al. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998 21 : 579 83.
49. Knox JJ, Siu LL, Chen E, et al. A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005 41 : 523 30.
50. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004 94 : 1140 6.
51. Kornbrust DJ, MacDonald JS, Peter CP, et al. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 1989 248 : 498 505.